Related Experiment Videos
Plasma exchange for Guillain-Barré syndrome
J C Raphaël1, S Chevret, R A Hughes
1Service de Réanimation Médicale, Hôpital Raymond Poincaré, Garches, France, 92380. jean-claude.raphael@rpc.ap-hop-paris.fr
The Cochrane Database of Systematic Reviews
|June 22, 2002
Summary
Plasma exchange (PE) is the first proven treatment superior to supportive care for Guillain-Barré syndrome (GBS). It accelerates recovery and improves outcomes, establishing it as a benchmark for new GBS therapies.
Area of Science:
- Neurology
- Immunology
- Critical Care Medicine
Background:
- Guillain-Barré syndrome (GBS) is an autoimmune disorder causing acute, paralyzing inflammation of peripheral nerves.
- Plasma exchange (PE) removes harmful antibodies and factors from the blood, offering a potential treatment avenue.
Purpose of the Study:
- To systematically review the efficacy of plasma exchange (PE) in treating Guillain-Barré syndrome (GBS).
Main Methods:
- Searched the Cochrane Neuromuscular Disease Trial Register for randomized trials on PE for GBS.
- Included randomized and quasi-randomized trials comparing PE to sham exchange or supportive care.
- Data extraction and analysis performed by multiple reviewers to ensure accuracy.
Main Results:
- Six trials (649 patients) showed PE significantly improved walking recovery time and disability grades at four weeks compared to supportive treatment.
- PE reduced the need for and duration of mechanical ventilation and improved long-term recovery.
- Benefits were observed across mild, moderate, and severe GBS cases, with optimal timing within seven days of onset.
Conclusions:
- Plasma exchange (PE) is the first treatment proven superior to supportive care for Guillain-Barré syndrome (GBS).
- PE should be the benchmark for evaluating new GBS treatments like intravenous immunoglobulin.
- Optimal PE protocols involve 2 sessions for mild, 4 for moderate, and potentially 4-6 for severe GBS, with earlier treatment yielding better results.